Abeona Therapeutics Inc.

NASDAQ:ABEO

Biotechnology

Healthcare
$2.73 +1.06%

+$0.06 today

Market cap
$156.01M
Beta
1.35
P/E (TTM)
4.9
EPS (TTM)
$1.17
52W Low $4.00High $7.54

Volume 1.71M

Average 1.12M

ABEO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Abeona Therapeutics Inc.NASDAQ: ABEO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $3.57M, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $6.99M. Over 3 fiscal years it compounded at +50.4% a year.

Context

  • Cost of revenue amounted to 26.3% of revenue in FY2025.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly cost of revenue holds near $3.57M or moves back toward the trailing-twelve-month quarterly average of $1.75M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.57M+25.7% QoQ
Last fiscal yearDec 2025
$1.53M-47.3% YoY
LTMMar 2026
$6.99M+800.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-47.3%——
3-year CAGR+50.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
1.53M USD
Year-over-year change
-47.3%

Cost of Revenue vs competitors

How ABEO compares with its peers on the latest reported figures

  • ABEO's LTM Mar 2026 cost of revenue of $6.99M is the 6th highest of the 10 companies compared; the peer median is $16.18M.
  • Its year-over-year change of +800.8% is the highest of 6, against a peer median of -46.2%.
  • Cost of revenue amounts to 48.1% of revenue for ABEO, versus a peer median of 44.9%.
ABEO Competitors Peer median
Cost of Revenue for ABEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$68.13M -46.2%—186.7%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$58.03M -9.7%+1.8%25.5%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$21.94M ——77.7%
HUMAHumacyte, Inc.LTM Mar 2026$17.11M +85.4%+27.3%848.5%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$16.18M -62.1%-87.7%22.8%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$6.99M +800.8%+50.4%48.1%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$4M ——8.8%
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 ———
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$0 ———
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$101K -104.8%-1.1%44.9%
Peer median (excluding ABEO) $16.18M-46.2%+0.4%44.9%

Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3M1.41M3.5M05.82M
Cost of Revenue0450K1.61M2.91M1.53M
Gross Profit3M964K1.9M(2.91M)4.29M
Gross Margin100.0%68.2%54.1%—73.7%
Research & Development38.73M28.97M31.09M34.36M26.81M
Selling, General & Admin21.64M17.26M19M29.85M65.03M
Operating Expenses92.84M51.88M49.03M61.3M93.74M
Depreciation & Amortization4.46M4.58M3.2M2.91M3.56M
EBITDA(76.82M)(34.38M)(50.57M)(56.62M)78.59M
EBITDA Margin-2560.5%-2431.6%-1444.9%—1350.3%
Operating Income(89.84M)(50.92M)(47.14M)(64.21M)(89.45M)
Operating Margin-2994.5%-3600.8%-1346.7%—-1536.9%
Interest Income40K431K2.12M4.25M5.56M
Interest Expense3.66M736K418K4.21M3.74M
Other Income / Expenses4.9M11.22M(7.05M)477K160.73M
Income Before Tax(84.94M)(39.7M)(54.19M)(63.73M)71.28M
Pre-Tax Margin-2831.2%-2807.4%-1548.2%—1224.8%
Income Tax Expense0000100K
Net Income(84.94M)(39.7M)(54.19M)(63.73M)71.18M
Net Margin-2831.2%-2807.4%-1548.2%—1223.1%
EPS (Basic)(21.50)(5.53)(2.53)(1.55)1.34
EPS (Diluted)(21.50)(5.53)(2.53)(1.55)1.01
Weighted Avg Shares3.94M7.86M21.38M41.05M52.95M
Weighted Avg Shares (Diluted)3.94M7.86M21.38M41.05M66.14M

Abeona Therapeutics Inc.

NASDAQ:ABEO

Intrinsic Alpha fair value

Locked

Current Price

$2.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.